Multiple Sclerosis



Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis


Condition:   Multiple Sclerosis
Interventions:   Biological: Autologous Hematopoietic Stem Cell;   Drug: BEAM Regimen
Sponsor:   Makati Medical Center
Recruiting - verified May 2017


A Multicenter Observational Study to Evaluate Pediatric Multiple Sclerosis in Brazil


Condition:   Multiple Sclerosis
Interventions:   Diagnostic Test: anti-aquaporin-4 antibody;   Diagnostic Test: anti-myelin oligodendrocyte glycoprotein
Sponsors:   Pontificia Universidade Católica do Rio Grande do Sul;   TEVA
Recruiting - verified March 2017


Pilot Diet Study for Multiple Sclerosis


Condition:   Multiple Sclerosis
Interventions:   Behavioral: Dietary Intervention;   Behavioral: Non-dietary Intervention Arm
Sponsor:   Icahn School of Medicine at Mount Sinai
Recruiting - verified December 2016


Swiss Multiple Sclerosis Registry


Condition:   Multiple Sclerosis
Intervention:  
Sponsors:   Swiss Multiple Sclerosis Registry;   University of Zurich, Epidemiology, Biostatistics and Prevention Institute;   Schweizerische Multiple Sklerose Gesellschaft
Recruiting - verified November 2016


Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis


Condition:   Multiple Sclerosis
Interventions:   Biological: Ublituximab;   Drug: Placebo
Sponsor:   TG Therapeutics, Inc.
Recruiting - verified January 2017


Pathological Basis of MRI Signal Changes in Multiple Sclerosis


Condition:   Multiple Sclerosis
Intervention:  
Sponsor:   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified December 6, 2016


[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis


Condition:   Multiple Sclerosis
Intervention:   Drug: ABT-555
Sponsor:   AbbVie
Terminated - verified February 2017


Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis


Condition:   Multiple Sclerosis
Interventions:   Drug: ponesimod;   Drug: teriflunomide
Sponsor:   Actelion
Active, not recruiting - verified April 2017


Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension


Condition:   Multiple Sclerosis
Intervention:   Other: Observational Cognitive assessments
Sponsors:   Clinique Neuro-Outaouais;   CogState Ltd.
Active, not recruiting - verified July 2016


Trekking Poles to Aid Multiple Sclerosis Gait Impairment


Condition:   Multiple Sclerosis
Interventions:   Other: No device;   Device: Single-point cane (SPC);   Device: Four-point cane (FPC);   Device: Trekking pole (TP).
Sponsor:   Rowan University
Recruiting - verified July 2016


Effect of MD1003 in Spinal Progressive Multiple Sclerosis


Condition:   Multiple Sclerosis
Interventions:   Drug: MD1003 100mg capsule;   Drug: Placebo
Sponsor:   MedDay Pharmaceuticals SA
Active, not recruiting - verified March 2017


Physical Telerehabilitation in Veterans With Multiple Sclerosis


Condition:   Multiple Sclerosis
Intervention:   Device: Multiple Sclerosis Home Automated Telemanagement (MS HAT) system
Sponsors:   University of Maryland;   Baltimore VA Medical Center
Completed - verified May 2017


Upper Limbs Intervention in Multiple Sclerosis


Condition:   Multiple Sclerosis
Interventions:   Other: Upper limbs intervention;   Other: Usual treatment
Sponsor:   Universidad de Granada
Completed - verified October 2016


A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)


Condition:   Multiple Sclerosis
Interventions:   Biological: PF-06342674 0.25 mg/kg;   Biological: Placebo;   Biological: PF-06342674 1.5 mg/kg;   Biological: PF-06342674 6.0 mg/kg
Sponsor:   Pfizer
Terminated - verified November 2016


Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis


Condition:   Multiple Sclerosis
Interventions:   Drug: Interferon beta-1a i.m. injections;   Drug: Fingolimod oral capsules;   Drug: Placebo oral capsule;   Drug: Placebo i.m. injection
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified November 2016


Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis


Condition:   Multiple Sclerosis
Intervention:   Drug: Fampridine
Sponsor:   Biogen
Completed - verified February 2017


The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis


Condition:   Multiple Sclerosis
Intervention:   Drug: Tysabri ® (Natalizumab)
Sponsor:   University of South Florida
Completed - verified February 2017


Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)


Condition:   Multiple Sclerosis
Interventions:   Other: Progressive exercise;   Device: Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV;   Other: Modified paleolithic diet;   Dietary Supplement: Omega 3 fatty acids;   Dietary Supplement: Full Spectrum vitamin;   Dietary Supplement: Essential - hydroxytyrosol;   Dietary Supplement: Maltodextrin fiber supplement;   Dietary Supplement: Mineral boost (magnesium);   Dietary Supplement: Niacinamide;   Dietary Supplement: Methyl B12;   Dietary Supplement: Taurine;   Dietary Supplement: creatine;   Dietary Supplement: thiamine;   Dietary Supplement: riboflavin;   Dietary Supplement: N acetylcysteine;   Dietary Supplement: alpha lipoic acid;   Dietary Supplement: L acetyl carnitine;   Dietary Supplement: methyl folate;   Dietary Supplement: coenzyme Q;   Behavioral: meditation;   Behavioral: self massage;   Behavioral: learning;   Dietary Supplement: Coconut oil
Sponsors:   University of Iowa;   Direct MS Canada;   DJO Incorporated;   Pinnaclife Inc.;   TZ Press, LLC
Completed - verified November 2016


Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis


Condition:   Multiple Sclerosis
Intervention:   Drug: Teriflunomide (HMR1726)
Sponsor:   Sanofi
Completed - verified December 2016


An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis


Condition:   Multiple Sclerosis
Interventions:   Drug: Placebo;   Drug: Teriflunomide
Sponsor:   Sanofi
Completed - verified May 2016


The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis


Condition:   Multiple Sclerosis
Interventions:   Biological: BG00002 (natalizumab);   Biological: keyhole limpet hemocyanin (KLH);   Biological: tetanus diphtheria toxoid vaccine (Td)
Sponsor:   Biogen
Completed - verified December 2016


Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis


Condition:   Multiple Sclerosis
Intervention:   Biological: hematopoetic stem cell infusion
Sponsor:   University of Louisville
Active, not recruiting - verified May 2017


Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks


Condition:   Multiple Sclerosis
Interventions:   Drug: megadose oral methylprednisolone;   Drug: IV methylprednisolone
Sponsors:   Fred Lublin;   National Multiple Sclerosis Society;   Pfizer
Terminated - verified April 2017


Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study


Condition:   Multiple Sclerosis
Interventions:   Procedure: Hematopoietic Stem Cell Therapy;   Drug: Standard treatment with a conventional drug
Sponsors:   Northwestern University;   Uppsala University;   Sheffield Teaching Hospitals NHS Foundation Trust;   University of Sao Paulo
Active, not recruiting - verified May 2017


Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)


Condition:   Multiple Sclerosis
Intervention:  
Sponsor:   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 16, 2017

Refine Your Search Advanced Search